Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P08908 (5-HT1A)
 5,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serotonin (5-HT) plays a major role as a neurotransmitter in the brain and large amounts are found in blood platelets. 5-HT release can be induced by action potentials invading the nerve terminals and by platelet aggregation. The targets of 5-HT are specific receptors mediating a wide variety of central and peripheral effects. For two of the main 5-HT receptor classes, the 5-HT2 and 5-HT3 receptors, selective antagonists are available, but this is not the case for the heterogeneous population of 5-HT1 receptors. In addition, the drugs with antagonistic properties at the 5-HT1A, 5-HT1B, 5-HT1C, and 5-HT1D receptors block other 5-HT receptors or even entirely different receptors (e.g., beta-adrenoceptors); as a rule, they do not discriminate between the four 5-HT receptor subtypes. Identification and characterization of these subtypes is further complicated by the fact that, with the exception of drugs activating 5-HT1A receptors, e.g., 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and urapidil; no subtype-selective agonists are available. Hence, the pharmacological characterization of a 5-HT1 receptor must be based on experiments with several putative 5-HT receptor agonists and antagonists with an overlapping profile of affinities for the various 5-HT1 receptor subclasses. The 5-HT1A receptor is the best-defined subclass and has already been cloned. It has been identified on cell bodies of 5-HT neurons in the raphe nuclei, and it mediates inhibition of cell firing.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Identification and classification of 5-HT1 receptor subtypes. 170 82

The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the 5-HT autoreceptor defined by inhibition of [3H]-5-HT release. In Percoll gradient Fractions 3 and 4 of spinal cord synaptosomes, a single saturable binding site for [125I]ICYP with a maximum binding of 70 and 134 fmol/mg, respectively, was demonstrated in the presence of 30 microM isoproterenol. The Kd of 0.16 nM did not vary between fractions. Competition for [125I]ICYP binding by various 5-HT agonists and antagonists also indicated a single site model based on a Hill coefficient of approximately 1.0. The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites. Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT. Compounds with activity at 5-HT1A, 5-HT1C, 5-HT2 or 5-HT3 sites were inactive. A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193). Although [125I]ICYP binding was unaltered, alpha-2 agonists such as clonidine, norepinephrine and UK 14304 [5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline) as well as the alpha-2 antagonists rauwolscine and yohimbine also decreased the K(+)-stimulated release of [3H]-5-HT and phentolamine, an alpha-2 antagonist increased release. The action of these alpha-2 compounds to alter [3H]-5-HT release suggests the presence of heteroreceptors localized on 5-HT terminals in the spinal cord. These results point out that [125I]ICYP identifies the 5-HT1B receptor, and affinity of compounds for this site predicts action at the 5-HT1B autoreceptor.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Characterization of 5-hydroxytryptamine1B receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of [3H]-5-hydroxytryptamine release. 173 11

Intracellular recordings in vitro from a variety of central neuronal types have shown both inhibition and excitation to be modulatory consequences of serotonin (5-HT) receptor activation. These responses can be seen in isolation or in some cases (e.g. hippocampal pyramidal cells) as a complex biphasic combination of hyperpolarisation followed by depolarisation, suggesting overall control of neuronal excitability may be dependent on the interaction between activation of more than one post-synaptic receptor and/or mechanism. Our studies have confirmed the 5-HT evoked depolarisation of rat facial motorneurones (FM's) and the hyperpolarisation seen in presumed serotonergic neurones of the dorsal raphe nucleus (DRN) to be the result of opposite effects on K+ ion permeability. Suppression of a resting K+ conductance leads to depolarisation while activation leads to hyperpolarisation. The same mechanisms appear to be responsible for the 5-HT evoked responses in hippocampal pyramidal cells but in addition there is also a suppression of a Ca++ dependent K+ conductance responsible for the long spike after hyperpolarisation (AHP). Data from the hippocampus and DRN indicate the 5-HT induced hyperpolarisation to be sensitive to Pertussis Toxin (PTX) and irreversibly mimicked by GTP gamma S, a non-hydrolysable analogue of GTP, suggesting the involvement of a G protein in K+ channel activation. The mechanism of K+ channel closure is less clear as it is unaffected by PTX or activation of adenylate cyclase, however there is indirect evidence that the phosphoinositide pathway may be involved from the cloned 5-HT1C receptor which also closes a K+ channel in cell lines. The results show that hyperpolarisation evoked by 5-HT in the hippocampus and DRN to be mimicked and blocked by 5-HT1A agonists and antagonists. However, the depolarisations in the hippocampus and FM's are mediated by site-dependent receptors with profiles which do not fit into the current 5-HT receptor subtype classification.
 ...
PMID:Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability. 175 7

The predominant psychobiological hypotheses regarding the pathophysiology of obsessive-compulsive disorder (OCD) are that a selective basal ganglia dysfunction and a dysregulation of one or several central serotonin (5-HT) subsystem are related to at least some aspects of the syndrome. Recent neuroanatomical, -pharmacological, and -ethological studies indicate a complex perceptual and cognitive role for the basal ganglia, particularly the striatum and the pallidum, in addition to the well-established motor functions. Obsessive-compulsive symptoms in syndromes with extrapyramidal-motor dysfunction, such as Gilles de la Tourette syndrome or Chorea minor (Sydenham), response to specific pharmacotherapy, behavioural therapy, and psychosurgery, as well as findings derived from brain imaging studies including positron emission tomography (PET) support the view of a frontal cortex/basal ganglia dysfunction in OCD. In addition, growing evidence suggests that potent inhibitors of 5-HT reuptake and other 5-HT subsystem-selective agents, such as the azapirones with partial agonist properties at the 5-HT1A receptor, are effective in OCD not only has improved the therapeutic perspective but may also reveal clues to the aetiopathogenesis of OCD. Much of this evidence has resulted from the discovery of multiple receptors and signal transduction pathways for 5-HT and from experiments relating the action of 5-HT receptor-selective agents to discrete effects in different subsystems. Among these 5-HT subsystems the 5-HT1D and 5-HT1A receptor-effector system complex appears to play a central role in the pathophysiology of OCD symptoms and the mechanism of action of antiobsessional drugs. Recent psychoneurobiological findings are reviewed briefly and evaluated in the context of the 5-HT and basal ganglia hypothesis of OCD.
 ...
PMID:[Psychobiology of compulsive disease]. 176 Dec 69

Enteric neural 5-HT receptors were analyzed and related to possible physiological actions of 5-HT. Receptors were identified electrophysiologically with intracellular microelectrodes and by studies of the binding of radioligands. Radioligand binding was assessed by rapid filtration and by radioautography. Three subtypes of 5-HT receptor, 5-HT1P, 5-HT3, and 5-HT1A, were identified. 5-HT1P receptors were found to mediate slow depolarizations of myenteric neurons that were associated with a decrease in membrane conductance. These responses were inhibited by 5-HTP-DP and by BRL 24924 and mimicked by 5- and 6-hydroxyindalpine. 5-HT1P receptors were labeled with high affinity by 3H-5-HT and were located on both submucosal and myenteric neurons and on processes of intrinsic neurons in the lamina propria. Serotonergic EPSPs were found to be mediated by 5-HT1P receptors; it is postulated that 5-HT1P receptors may be involved in initiation of the peristaltic reflex and in the regulation of gastic emptying. 5-HT3 receptors have been shown to be responsible for fast depolarizations of myenteric and submucosal neurons associated with a rise in membrane conductance. These responses are antagonized by ICS 205-930 and mimicked by 2-methyl-5-HT. 5-HT1A receptors have been reported by others to mediate hyperpolarizing responses of myenteric neurons associated with a rise in membrane conductance. Hyperpolarizing responses are also elicited by the 5-HT1A agonist, 8-OH-DPAT. No physiological role has yet been identified for 5-HT3 or 5-HT1A receptors in the ENS.
 ...
PMID:Serotonin: its role and receptors in enteric neurotransmission. 177 68

The effects of a number of 5-HT receptor ligands were examined on nonopioid defensive analgesia in male DBA/2 mice. MDL 73005EF (0.05-1.0 mg/kg), a selective 5-HT1A receptor agonist, potently and dose-dependently inhibited the analgesic consequences of social defeat. CGS 12066B (0.5-10.0 mg/kg) and MK-212 (0.3-10.0 mg/kg), selective agonists for 5-HT1B and 5-HT1C sites, respectively, failed to influence this particular form of adaptive pain inhibition. Two 5-HT2/1C receptor antagonists, ritanserin (0.05-10.0 mg/kg) and ICI 169.369 (0.3-10.0 mg/kg), were also devoid of specific effects upon defensive analgesia. Both ritanserin and ICI 169,369 were found to have intrinsic analgetic efficacy and to induce behavioural changes indicative of increased defensiveness. These data, together with previous findings, confirm the specific involvement of 5-HT1A receptor mechanisms in the analgesic consequences of social defeat in male mice. Results are discussed in relation to the role of anxiety in adaptive pain inhibition.
 ...
PMID:Differential effects of novel ligands for 5-HT receptor subtypes on nonopioid defensive analgesia in male mice. 179 10

Intrathecal administration (ith) of 5-hydroxytryptamine (5-HT, 1.56, 3.125, 6.25 and 12.5 micrograms/10 microliters) to conscious rats produced a marked dose-dependent hypertensive effect without significant change in heart rate (HR). Ith administration of fluoxetine (10 micrograms/microliters), one of the presynaptic reuptake inhibitors of 5-HT, produced a marked increase in the mean arterial blood pressure (mABP). This effect could be prevented by a pretreatment with cinanserin (25 micrograms ith) as a blocker of 5-HT receptor. It was further observed that ith of 8-OH-DAPT (2.5, 5, 10 micrograms/10 microliters), a 5-HT1A receptor agonist, produced a dose-dependent increase of mABP and lowering of HR. However, ith of 5-HT3 receptor agonist 2-Methylserotonin (25, 50, 100 micrograms/10 microliters), decreased mABP markedly without change in HR. The results indicate that 5-HT in the spinal cord may extra hypertensive effect via 5-HT1A receptor and a hypotensive effect via 5-HT3 receptor. This gives a possible explanation about the conflicting reports concerning the effect of 5-HT in the central nervous system on blood pressure.
 ...
PMID:[Cardiovascular reactions mediated by 5-HT1A and 5-HT3 receptors in the spinal cord of conscious rats]. 179 18

Four major families of serotonin (5-hydroxytryptamine; 5-HT) receptors have been identified: 5-HT1, 5-HT2, 5-HT3 and 5-HT4. At this time, there is a general consensus that the 5-HT1 family can be further subdivided into 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, and 5-HT1P subpopulations. In addition, there are several other populations of less well-defined 5-HT receptors. The purpose of this presentation is to discuss 5-HT receptor nomenclature and the agents that are commonly used to investigate each receptor population in as much as it will serve to provide background for the remainder of the symposium. There is presently available an abundance of serotonergic agents; however, these agents are only semiselective, and none can be considered truly selective for a particular population of 5-HT receptors. As useful as these agents have been for the identification and characterization of 5-HT receptors, there remains a need for the development of new, more selective ligands.
 ...
PMID:Serotonin receptors and their ligands: a lack of selective agents. 181 55

The 5-HT1A receptor has been one of the most studied 5-HT receptor subtypes in terms of its pharmacologic profile. Comparisons of various studies of structure-activity relationships (SAR) at this receptor shows an emerging profile for this receptor's pharmacophore. The present discussion focuses on the findings generated with relatively small molecules that can be considered as analogs of serotonin itself and that illustrate some of the structural properties that are important for high-affinity recognition by the receptor. Most of the SAR work has been based on the affinities of compounds for the receptor as determined by the radioligand-binding technique, which has a significant limitation in that it cannot define the intrinsic activity of compounds at the receptor. This problem can be addressed by functional assays, and an example of SAR at the 5-HT1A receptor-coupled adenylate cyclase system is provided.
 ...
PMID:Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity. 181 58

The recent cloning of three types of 5-hydroxytryptamine (5-HT, serotonin) receptors substantiates radioligand-based definitions of 5-HT receptors, and provides a framework in which to understand the function and evolution of the receptors. The primary sequences determined by molecular cloning of the 5-HT1c, 5-HT1a and 5-HT2 receptors place each of these 5-HT receptor subtypes into the class of G protein-coupled receptors. These receptors all share similar functional and structural features. Each receptor is positioned in the lipid bilayer with seven membrane-spanning domains and corresponding intracellular and extracellular domains. By analogy to the known functional structures of the beta-adrenergic receptor, the binding site of 5-HT is proposed to be in the membrane domains and the intracellular domain is important for G protein interaction. The primary sequences and the second messenger systems of the receptors indicate the 5-HT2 and 5-HT1c receptors are closely related, whereas the 5-HT1a receptor is more distantly related to the 5-HT2 and 5-HT1c receptors.
 ...
PMID:Molecular biology of serotonin (5-HT) receptors. 181 59


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>